ScholarMate
English简体中文繁體中文
客服熱線:400-1616-289
登入註冊
期刊論文

Biological landscape and nanostructural view in development and reversal of oxaliplatin resistance in colorectal cancer

Hashemi, Mehrdad; Esbati, Nastaran; Rashidi, Mohsen; Gholami, Sadaf; Raesi, Rasoul; Bidoki, Seyed Shahabadin; Goharrizi, Mohammad Ali Sheikh Beig; Motlagh, Yasamin Sadat Mousavi; Khorrami, Ramin; Tavakolpournegari, Alireza; Nabavi, Noushin; Zou, Rongjun; Mohammadnahal, Leila*; Entezari, Maliheh*; Taheriazam, Afshin*; Hushmandi, Kiavash*广东省人民医院; 广州中医药大学; 6
Translational Oncology2024-2DOI: 10.1016/j.tranon.2023.101846
14閱讀
引用收藏
分享

摘要

The treatment of cancer patients has been mainly followed using chemotherapy and it is a gold standard in improving prognosis and survival rate of patients. Oxaliplatin (OXA) is a third-platinum anti-cancer agent that reduces DNA synthesis in cancer cells to interfere with their growth and cell cycle progression. In spite of promising results of using OXA in cancer chemotherapy, the process of drug resistance has made some challenges. OXA is commonly applied in treatment of colorectal cancer (CRC) as a malignancy of gastrointestinal tract and when CRC cells increase their proliferation and metastasis, they can obtain resistance to OXA chemotherapy. A number of molecular factors such as CHK2, SIRT1, c-Myc, LATS2 and FOXC1 have been considered as regulators of OXA response in CRC cells. The non-coding RNAs are able to function as master regulator of other molecular pathways in modulating OXA resistance. There is a close association between molecular mechanisms such as apoptosis, autophagy, glycolysis and EMT with OXA resistance, so that apoptosis inhibition, pro-survival autophagy induction and stimulation of EMT and glycolysis can induce OXA resistance in CRC cells. A number of anti-tumor compounds including astragaloside IV, resveratrol and nobiletin are able to enhance OXA sensitivity in CRC cells. Nanoparticles for increasing potential of OXA in CRC suppression and reversing OXA resistance have been employed in cancer chemotherapy. These subjects are covered in this review article to shed light on molecular factors resulting in OXA resistance.

學科與關鍵詞

關鍵詞
OxaliplatinCancer chemotherapyDrug resistanceMolecular pathwaysColorectal cancer
相關
載入中…
  • Effective Delivery of siRNA-Loaded Nanoparticles for Overcoming Oxaliplatin Resistance in Colorectal Cancer
    Zhou, Yue; Zhang, Qing; Wang, Minjia; Huang, Chengzhi*; Yao, Xueqing*Frontiers in Oncology, 2022, 12: 827891.被引 5
  • Effective Delivery of siRNA-Loaded Nanoparticles for Overcoming Oxaliplatin Resistance in Colorectal Cancer (vol 12, 827891, 2022)
    Zhou, Yue; Zhang, Qing; Wang, Minjia; Huang, Chengzhi*; Yao, Xueqing*Frontiers in Oncology, 2022, 12: 916983.被引 1
  • Precision medicine-guided co-delivery of ASPN siRNA and oxaliplatin by nanoparticles to overcome chemoresistance of colorectal cancer
    Huang, Cheng-Zhi; Zhou, Yue; Tong, Qi-Song; Duan, Qi-Jia; Zhang, Qing; Du, Jin-Zhi*; Yao, Xue-Qing*Biomaterials, 2022, 290: 121827.被引 8
查看全部 →

發表資訊

論文狀態
公開發表
期刊
Translational Oncology
發表日期
2024-02
卷期
第 40 卷
頁碼
101846
DOI
10.1016/j.tranon.2023.101846
語言
ENGLISH
成果收錄
SCIE

作者

  • H

    Hashemi, Mehrdad (第一作者)

  • E

    Esbati, Nastaran

查看全部 16 位作者收起作者
  • R

    Rashidi, Mohsen

  • G

    Gholami, Sadaf

  • R

    Raesi, Rasoul

  • B

    Bidoki, Seyed Shahabadin

  • G

    Goharrizi, Mohammad Ali Sheikh Beig

  • M

    Motlagh, Yasamin Sadat Mousavi

  • K

    Khorrami, Ramin

  • T

    Tavakolpournegari, Alireza

  • N

    Nabavi, Noushin

    6

  • Z

    Zou, Rongjun

    2 · guangdong prov hosp · guangzhou univ chinese med

  • M

    Mohammadnahal, Leila (通訊)

  • E

    Entezari, Maliheh (通訊)

  • T

    Taheriazam, Afshin (通訊)

  • H

    Hushmandi, Kiavash (通訊)

登入解鎖更多功能

  • 收藏這篇,隨時在「我的 · 收藏」找回
  • 認領你的成果,生成推廣素材
  • 關注作者獲取最新成果
  • 加入項目組、協同寫作
註冊 / 登入

產品服務

  • 科研之友
  • 創新城
  • 科創雲

服務支援

  • 幫助中心
  • 隱私政策
  • 服務條款

聯絡方式

線上客服:【】
客服熱線:400-1616-289
電子郵件:support@scholarmate.com

關注或下載科研之友

微信 QR Code
微信公眾號
客戶端下載 QR Code
下載客戶端
科研成果科研人員科研機構科研動態愛瑞思軟件

©2026 深圳市科研之友网络服务有限公司

公安備案圖示粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417